Sapio has established a unique, highly scalable, best in class lab informatics platform with multiple avenues for growth and expansion Strongly positioned to address an international, high growth market demanding new data-driven and fit for purpose AI assisted lab informatics technologies GHO combines its deep life science market knowledge, network and expertise to support founder…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Biocare Medical, regarding its acquisition of Empire Genomics. Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridisation) instrumentation and reagents, announces the acquisition…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Velocity Clinical, regarding its expansion into the UK. Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, announced its expansion into the UK with the acquisition of multi-site company Egin Research.…
read more
A high growth CDMO with integrated capabilities across the drug development lifecycle, including high-demand areas of sterile fill-finish drug product manufacturing, biologic and small molecule lab services, cGMP biostorage and pharma services Recent acquisitions and significant investment in new capacity and state of the art lab space will support Alcami’s continued high growth potential GHO…
read more
Appointment will support GHO with deal origination and accelerating growth across the portfolio, leveraging extensive experience in contract research, commercialisation and international expansion. London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Alistair Macdonald as Operating Partner. Alistair has more…
read more
Acquisition of MedPharmics gives Velocity access to African American and Native American patient populations. London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Velocity Clinical, regarding the acquisition of MedPharmics. Velocity Clinical Research (“Velocity”), the leading integrated research site organisation,…
read more
Combination creates global leader in process development and GMP manufacturing of advanced cell and gene therapies with transatlantic footprint in the US and UK Key leadership, staff and shareholders of both businesses will remain and have reinvested in the new entity, with a shared strategic vision for growth London, UK – Global Healthcare Opportunities, or GHO…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Velocity Clinical Research, regarding the acquisition of Clinical Research Hamburg, Germany. Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announced that it has acquired its first European site, Clinical Research Hamburg,…
read more
Combined offering will enable life sciences companies to generate insights and assess commercial viability faster and more comprehensively than ever before London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Genesis Research (“Genesis” or “the Company”), regarding the acquisition of…
read more
Validant has grown into the global leader in quality, compliance & regulatory healthcare consulting Fresh capital to fuel continued geographic and product / service line expansion Management and GHO are partnering with Goldman Sachs Asset Management and LACERA to support the next stage of the company’s growth London, UK – Global Healthcare Opportunities, or GHO…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Sterling Pharma Solutions, regarding the acquisition of a Novartis facility in Ringaskiddy, Ireland. Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it had reached an agreement with…
read more
RoslinCT positioned as market leader in advanced cell therapies with a focus on innovation and quality GHO partnering with existing management to support operational growth, customer acquisition and product diversification Leveraging GHO’s sector network to expand international customer base London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in…
read more
Investment to accelerate growth amid an increasing market demand for Immunohistochemistry instruments and reagents Management will leverage GHO’s extensive healthcare expertise to accelerate R&D, product launches and international expansion GHO in partnership with existing investor Excellere Partners will continue to support the Biocare Medical team in accelerating strategic growth initiatives London, UK – Global Healthcare Opportunities,…
read more
Under GHO’s ownership BioAgilytix has become a leader among global CRO’s following strong organic and inorganic growth – with significant investment driving expansion in operational capacity and capabilities as well as in international footprint. With a best of breed reputation for high-quality bioanalytical services, BioAgilytix supports the development and commercialisation of novel therapeutics to improve…
read more
Genesis is a market leader in tech-enabled RWE and HEOR Management to pursue global expansion, leveraging GHO’s European expertise London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research (‘Genesis’), a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics…
read more
Manuela will lead GHO’s sustainable investment strategy, driving the integration of ESG considerations within the investment process and portfolio value creation plans London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the appointment of Manuela Rankine as Director of Sustainable Investing. In this newly created…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company X-Chem, regarding the acquisitions of Glamorous AI and ComInnex. X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognised leader in generating actionable results to drive small molecule drug discovery, announced…
read more
GHO partnering with the Sanner family and existing management to drive global growth Sanner positioned as market leader with a focus on quality and innovation Management to pursue global expansion, leveraging GHO’s international expertise London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, announces its investment…
read more
Investment from large investors attracted into SMO industry Consolidation of multi-site networks indicates maturing market London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Velocity Clinical, regarding the acquisition of 11 new US sites. Velocity Clinical Research (“Velocity”)…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Ardena, regarding the acquisition of Idifarma from Suanfarma and Sodena. Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced today that it has acquired Idifarma, a leading…
read more
GHO partnering with existing management team to accelerate global growth ClearView positioned as market leader in an industry experiencing strong tailwinds Management to pursue international markets and broaden service offering, leveraging GHO’s unparalleled sector expertise London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, and the founding…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, BioAgilytix, regarding the acquisitions of 360biolabs® and MicroConstants.
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Velocity Clinical, regarding the strengthening of its management team as part of expansion in Europe.
read more
c.€5bn AUM positions GHO as Europe’s Reference Investor in global healthcare Significantly oversubscribed Fund closes within four months of entering the market GHO welcomes new team hires, the addition of Operating Partners and announces the opening of US office on the East Coast in H2 2021 London, UK – GHO Capital (Global Healthcare Opportunities), the…
read more
Bicoastal expansion — New York and California London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Velocity Clinical, regarding the additon of two new sites to its US network. Leading US-based integrated site company, Velocity Clinical Research, today announces it has…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Ardena, regarding a major investment to expand across Belgium, Sweden and The Netherlands. Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), in partnership with GHO Capital, announced…
read more
The partnership expands Two Labs’ suite of services and broadens its integration competency to include government price reporting London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, Envision Pharma Group, regarding the acquisition of Riparian by Two Labs.…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, announces the sale of DNA Diagnostics Center (“DDC”) to Eurofins, a publicly traded global laboratory testing business. DDC is a multichannel, global leader in consumer-focused DNA testing, offering best in class DNA lab and testing services…
read more
Greenleaf CEO – Patrick Ronan – Named New CEO of Validant London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of Greenleaf Health. Validant, a leading global quality, compliance and regulatory consulting group (the Group), has acquired Greenleaf…
read more
Adds complementary training services to provide holistic customer support Deepens experience with high quality medical device consulting team Follows acquisitions of DataRevive and IDEC in 2019 and 2020 respectively London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of Velocity Clinical Research, from NaviMed Capital (“NaviMed”) and other investors, signalling how the business of running clinical trial sites is changing. Headquartered in Durham, North Carolina, Velocity operates 16 fully-owned sites across 11 US…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of ADC Bio. Global Contract Development and Manufacturing Organisation (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK based bioconjugation development services…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Envision Pharma Group, regarding the acquisition of doDOC. Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a…
read more
Appointments will support GHO through deal origination and portfolio company support, bringing extensive experience in market access, MedTech and advanced therapies from industry and consulting careers. London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, announces the appointment of David Miller and Geoffrey Hamilton-Fairley as Operating Partners.…
read more
Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder and CEO Jeffrey Albert to join X-Chem management team London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, X-Chem, regarding…
read more
Expands geographic reach with direct presence in Japan Expands breadth and depth of consultancy and implementation capabilities Establishes comprehensive Asian regulatory service with DataRevive in China and IDEC in Japan London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding…
read more
Acquisition follows increased investment in Envision from GHO Capital and its partners Two Labs brings market-leading commercialisation, strategic consulting, market access, and market intelligence solutions that span the full product life cycle Move builds on Envision’s established leadership position as the preferred tech-enabled scientific communications company for medical affairs, while deepening its presence in the…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, together with the existing Envision management team and employees, have increased their investment in Envision Pharma Group (“Envision” or the “Company”), a leading technology-enabled scientific communications company. The transaction sees GHO lead a consortium of its investors headed…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of Alcami’s Germantown, Wisconsin facility in the US. Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of Alcami’s…
read more
Panel of 15 potent antibodies selected that are optimally suited to clinical development and manufacturing Monoclonal antibodies have the potential to both treat infected patients and provide protection to the “at risk” population during the pandemic Viral neutralisation data independently verified by the National Institute for Biological Standards and Control (NIBSC) Project is part of an…
read more
Matt Clark named new Chief Executive Officer US-based X-Chem is the leading provider of small molecule discovery services to global biopharma using DNA-Encoded Library technology GHO to invest further in best-in-class technology and service proposition London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the…
read more
FairJourney’s combination with Iontas creates a leading global antibody discovery CRO with an international footprint FairJourney’s unique antibody discovery libraries and service portfolio to be complemented by Iontas’ proprietary mammalian display technology Group to have an unparalleled service and technology offering across antibody discovery, engineering, characterisation, and manufacturing services London, UK – Global Healthcare Opportunities, or…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Sterling Pharma Solutions, regarding the commencement of the production of potential COVID-19 treatment. Global Contract Development and Manufacturing Organisation (CDMO), Sterling Pharma Solutions, has commenced production of hydroxychloroquine (HCQ), a treatment currently…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, FairJourney Biologics, regarding the partnership with Iontas in search for SARS-CoV-2 treatment. FairJourney Biologics (Porto, Portugal) and Iontas (Cambridge, UK) today announce a partnership to expedite the identification of effective antibodies for…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Envision Pharma Group, regarding the acquisition of 90TEN. Global healthcare communications consultancy 90TEN has been acquired by Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions.…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, announces its investment to partner with the founding management team in FairJourney Biologics (‘FairJourney’), a leader in providing antibody discovery services to global biopharma. Established in 2012 in Porto, Portugal, FairJourney provides outsourced antibody discovery, engineering, production and…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, has acquired Ardena, a specialist contract development and manufacturing organisation (CDMO) focused on early phase drug development, from Mentha Capital and existing management. Ardena is a multi-service CDMO, assisting small-to-mid sized biopharma with services spanning the full development…
read more
€975m fundraise marks the largest ever specialist private equity fund dedicated to investing in European healthcare Fund II will invest in high growth healthcare subsectors, including outsourced services, pharma and medtech Oversubscribed fund is 50% larger than GHO’s 2015 maiden fund, demonstrating strong support from existing and new investors alike London, UK – Global Healthcare…
read more
Highly complementary transaction strengthens BioAgilytix’s ability to support all phases of biologics development; adds to growing cell and gene therapy expertise; increases laboratory capacity; expands team of seasoned bioanalytical scientists; broadens geographic reach. London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of DataRevive. Validant, a leading transatlantic quality, compliance and regulatory consulting group, has acquired DataRevive, a regulatory strategy and consultancy firm that focuses on supporting pharma and…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, today announces the sale of Caprion Biosciences (“Caprion”) to Arsenal Capital Partners, a leading specialised private equity firm that invests in middle-market healthcare and specialty industrials companies. Caprion is a specialised laboratory service business serving pharma and biotech…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from Quotient Sciences regarding its recapitalisation with global Private Equity Firm Permira: Quotient Sciences and global investment firm Permira today announced that a company backed by the Permira Funds has signed a definitive agreement to acquire…
read more
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Caprion BioSciences, regarding the acquisition of Serametrix Corporation. Caprion Biosciences announced that the company acquired Serametrix Corporation, a specialised provider of immune monitoring services headquartered in Carlsbad, California. Caprion plans to…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of CiVentiChem in the US. UK-based contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of CiVentiChem’s US facility located in Cary, North Carolina, US. The new…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, has acquired a majority stake, alongside Management, in Sterling Pharma Solutions (‘Sterling’ or the ‘Company’), a specialist in complex and difficult to manufacture APIs. Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of API development and manufacturing, with a reputation for…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, has acquired a majority stake in Validant, a leading quality, compliance and regulatory affairs consulting firm. Operating globally with offices in Europe and North America, Validant provides specialist consulting services, with a focus on quality, compliance and regulatory affairs, to a broad range of…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Caprion Biosciences, Inc. (“Caprion” or “the Company”) regarding the acquisition of US-based Primity Bio. Caprion Biosciences announced today that the company acquired Primity Bio Inc., a specialised provider of biomarker and immune monitoring services located in Fremont,…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, today announces the acquisition of Linimed Gruppe (“Linimed” or “the Company”), a leading provider of outpatient intensive care services across Germany, from Vitruvian Partners and the Linimed founders. Headquartered in Jena, Linimed Gruppe is one of the largest providers of outpatient intensive care in…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Quotient Sciences regarding its acquisition of Pharmaterials, a UK-based Contract Development and Manufacturing Organisation. Quotient Sciences (“Quotient”), the early phase drug development services provider, announced that it has acquired Pharmaterials, a contract development and manufacturing organisation (CDMO)…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Envision Pharma Group regarding its acquisition of Touch Creative Design Limited, a UK-based Pharma/Healthcare focused agency with multi-industry experience. To underpin their commitment to clients to provide pioneering scientific multichannel medical communication solutions alongside their purpose built industry-leading…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, is pleased to share today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of QS Pharma, increasing its US presence and adding high potency molecule capabilities to its existing operations. Addition of contract development and manufacturing organisation increases scale of business and…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of SeaView Research, expanding its existing operational footprint to the US. Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired SeaView Research (“SeaView”), expanding its…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company DNA Diagnostics Center ® (“DDC”) regarding the acquisition of the assets of IDENTIGENE®, LLC, a wholly owned subsidiary of Sorenson Genomics, LLC. As a significant consumer brand in parentage testing, distributed at over 20,000 retail store locations throughout…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, today announces the successful final close for GHO Capital Fund I LP, a €660 million private equity fund which has been raised to seize the highly attractive and underpenetrated investment opportunity in European healthcare. GHO Capital Fund I LP (“the Fund”) was significantly oversubscribed,…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Caprion Biosciences, Inc. (“Caprion” or “the Company”) regarding the acquisition of the assets of the immune monitoring laboratory of ImmuneHealth, ASBL. Located in Gosselies, Belgium, the ImmuneHealth laboratory will provide a fully operational immune monitoring laboratory infrastructure…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, today announces the acquisition of Caprion Biosciences, Inc. (“Caprion” or “the Company”), the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion is a specialist laboratory services company which provides testing services to pharmaceutical and biotechnology companies for…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, in collaboration with Ardian, the independent private investment company, has partnered with the Envision Pharma Group’s (“Envision”) leadership team to acquire Envision, a leading Medical Affairs-focused scientific communications and technology solutions provider, from the Halifax Group. The management team and employees, led by Brian…
read more
London, UK – GHO Capital, the European specialist investor in healthcare, has entered into an agreement to acquire the European commercial operations of Nicox S.A. (“Nicox”) (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and to acquire the entire issued share capital of Visufarma Spa (“Visufarma”), a private Italian ophthalmic company. The combined platform will…
read more
London, UK – GHO Capital, the European specialist healthcare investor, today announces the appointment of Ken Eichmann as Principal. The firm now has a dedicated healthcare team of 10 investment professionals. Ken is an experienced private equity investment professional who brings a wealth of origination, transaction execution and M&A expertise to GHO Capital. He previously…
read more
London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of Quotient Clinical (Quotient or the Company), a provider of outsourced, early-stage drug development services to the pharmaceutical industry. Headquartered in the UK and employing over 280 professionals, Quotient Clinical enables pharmaceutical and biotechnology customers to improve research and development productivity…
read more
London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of DNA Diagnostics Center (DDC or the Company), a world leader in the provision of specialist DNA-based diagnostic services, for a total transaction value of €104 million. Further details of the transaction were not disclosed. DDC is a market leading diagnostics…
read more
On Wednesday 18 March 2015, Andrea Ponti, Executive Partner and Founder at GHO Capital, will participate in a panel discussion at the European Medicines Agency’s “Science, Medicines, Health: Patients at the heart of future innovation” conference in London. Andrea will be giving an investor’s view on the regulatory environment in Europe. The invitation-only conference is…
read moreSubscribe to our email alerts
